Peritoneal Cancer - Pipeline Review, H2 2020

September 2020 | 1845 pages | ID: P1D31F5E446EN
Global Markets Direct

Abstracts

Peritoneal Cancer - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer - Pipeline Review, H2 2020, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.
Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 19, 87, 57, 3, 24, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 4 and 7 molecules, respectively.
Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Peritoneal Cancer - Overview
Peritoneal Cancer - Therapeutics Development
Peritoneal Cancer - Therapeutics Assessment
Peritoneal Cancer - Companies Involved in Therapeutics Development
Peritoneal Cancer - Drug Profiles
Peritoneal Cancer - Dormant Projects
Peritoneal Cancer - Discontinued Products
Peritoneal Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Peritoneal Cancer, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Peritoneal Cancer - Pipeline by AB Science SA, H2 2020
Peritoneal Cancer - Pipeline by AbbVie Inc, H2 2020
Peritoneal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2020
Peritoneal Cancer - Pipeline by AIM ImmunoTech Inc, H2 2020
Peritoneal Cancer - Pipeline by AiVita Biomedical Inc, H2 2020
Peritoneal Cancer - Pipeline by Aldeyra Therapeutics Inc, H2 2020
Peritoneal Cancer - Pipeline by ALX Oncology Inc, H2 2020
Peritoneal Cancer - Pipeline by Amgen Inc, H2 2020
Peritoneal Cancer - Pipeline by Anew Oncology Inc, H2 2020
Peritoneal Cancer - Pipeline by Antapodia Therapeutics Inc, H2 2020
Peritoneal Cancer - Pipeline by Apexigen Inc, H2 2020
Peritoneal Cancer - Pipeline by Apollomics Inc, H2 2020
Peritoneal Cancer - Pipeline by Apotex Inc, H2 2020
Peritoneal Cancer - Pipeline by Aravive Inc, H2 2020
Peritoneal Cancer - Pipeline by Arch Oncology Inc, H2 2020
Peritoneal Cancer - Dormant Projects, H2 2020
Peritoneal Cancer - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Peritoneal Cancer, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

AB Science SA
AbbVie Inc
Advenchen Laboratories LLC
AIM ImmunoTech Inc
AiVita Biomedical Inc
Aldeyra Therapeutics Inc
ALX Oncology Inc
Amgen Inc
Anew Oncology Inc
Antapodia Therapeutics Inc
Apexigen Inc
Apollomics Inc
Apotex Inc
Aravive Inc
Arch Oncology Inc
Arrien Pharmaceuticals LLC
Ascend Biopharmaceuticals Ltd
Ascenta Therapeutics Inc
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Basilea Pharmaceutica Ltd
Bayer AG
BeiGene Ltd
Bio-Path Holdings Inc
BioIntegrator Ltd
BioNTech SE
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Celldex Therapeutics Inc
Celsion Corp
Centus Biotherapeutics Ltd
CerRx Inc
Clover Biopharmaceuticals
Clovis Oncology Inc
Context Therapeutics LLC
Corcept Therapeutics Inc
Cotinga Pharmaceuticals Inc
Cristal Therapeutics BV
CytomX Therapeutics Inc
Dr. Reddy's Laboratories Ltd
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
Ellipses Pharma Ltd
ENB Therapeutics LLC
Epizyme Inc
Esperance Pharmaceuticals Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fujifilm Holdings Corp
Gene Techno Science Co Ltd
Genelux Corp
Genentech USA Inc
Genmab AS
Gilead Sciences Inc
GlaxoSmithKline Plc
Gradalis Inc
I-Mab
ImmunityBio Inc
Immunocore Ltd
ImmunoGen Inc
IMPACT Therapeutics Inc
IMV Inc
Incyte Corp
Infinity Pharmaceuticals Inc
Innate Pharma SA
Innovent Biologics Inc
InSight Biopharmaceuticals Ltd
InxMed Shanghai Co Ltd
Ionic Pharmaceuticals LLC
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Kupffer Biotherapeutics Inc
Kyowa Kirin Co Ltd
Laekna Therapeutics Shanghai Co Ltd
Leap Therapeutics Inc
Legend Biotech Corp
LintonPharm Co Ltd
Lipac Oncology LLC
Lokon Pharma AB
MabVax Therapeutics Holdings Inc
MaxCyte Inc
Merck & Co Inc
Merck KGaA
Mersana Therapeutics Inc
Millennium Pharmaceuticals Inc
Moderna Inc
Morvus Technology Ltd
MUCPharm Pty Ltd
Mycenax Biotech Inc
Northlake International LLC
Novartis AG
NuCana Plc
Oasmia Pharmaceutical AB
OBI Pharma Inc
Oncoinvent AS
Oncolytics Biotech Inc
OncoQuest Inc
Oncovir Inc
OncXerna Therapeutics Inc
Ono Pharmaceutical Co Ltd
Orano Med LLC
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
Plexxikon Inc
Polaris Pharmaceuticals Inc
Precigen Inc
Prestige BioPharma Pte Ltd
PsiOxus Therapeutics Ltd
PTC Therapeutics Inc
R-Pharm US LLC
Regeneron Pharmaceuticals Inc
Rgenix Inc
Richter Gedeon Nyrt
Rigel Pharmaceuticals Inc
Samyang Holdings Corp
Sanofi
SELLAS Life Sciences Group Inc
Shanghai De Novo Pharmatech Co Ltd
Shattuck Labs Inc
Shenzen SiBiono GeneTech Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Soricimed Biopharma Inc
Sotio AS
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Dainippon Pharma Oncology, Inc
Sutro Biopharma Inc
Synermore Biologics Co Ltd
Targovax ASA
Transgene SA
Vascular Biogenics Ltd
Verastem Inc
Vyriad Inc
Xencor Inc
Xynomic Pharmaceuticals Holdings Inc
Y-mAbs Therapeutics Inc
Zentalis Pharmaceuticals LLC